Most Read

The development programme commences immediately with an aim to introduce the vaccine in 2022, post regulatory approval. This vaccine will be developed with a potential for a multi-valent

The Couvet site is a state-of-the-art manufacturing facility with commercial-scale capacity to produce capsule and tablet dosage forms. For WuXi STA, the Couvet site will be its first

The antibody therapies, which are administered via intravenous infusion, have secured Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for treating high-risk patients mild

The authorisation was granted after the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency reviewed the primary data from the vaccine’s Phase III

Under the deal, the US-based biotech company has granted an exclusive, worldwide, royalty-bearing license to Takeda Pharmaceutical pertaining to cell and non-cell therapy products that modulate targets identified

VIR-7832, a neutralising Covid-19 antibody, attaches to an epitope on SARS-CoV-2 that is shared with SARS-CoV-1. According to GSK, the preclinical data suggests that VIR-7832 has two distinguishing

According to the India-based pharma company, the Sputnik V vaccine has been recommended by an independent data and safety monitoring board (DSMB) to advance to a phase 3

As per terms of the deal, Kymab will secure an upfront payment of up to $1.1bn from Sanofi. Kymab is also eligible to secure up to $350m based

The in vitro study, which was held by Pfizer and the University of Texas Medical Branch (UTMB), demonstrated that the antibodies from people subjected to the vaccine could